Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lifecore Biomedical (LFCR) Finished Goods: 2012-2018

Historic Finished Goods for Lifecore Biomedical (LFCR) over the last 7 years, with Nov 2018 value amounting to $13.9 million.

  • Lifecore Biomedical's Finished Goods rose 7.93% to $13.9 million in Q4 2018 from the same period last year, while for Nov 2018 it was $13.9 million, marking a year-over-year increase of 7.93%. This contributed to the annual value of $12.9 million for FY2018, which is 28.42% up from last year.
  • According to the latest figures from Q4 2018, Lifecore Biomedical's Finished Goods is $13.9 million, which was up 7.57% from $12.9 million recorded in Q3 2018.
  • In the past 5 years, Lifecore Biomedical's Finished Goods ranged from a high of $17.1 million in Q3 2016 and a low of $10.0 million during Q2 2017.
  • In the last 3 years, Lifecore Biomedical's Finished Goods had a median value of $12.7 million in 2016 and averaged $12.5 million.
  • In the last 5 years, Lifecore Biomedical's Finished Goods decreased by 26.16% in 2017 and then climbed by 28.42% in 2018.
  • Quarterly analysis of 5 years shows Lifecore Biomedical's Finished Goods stood at $14.3 million in 2014, then fell by 0.81% to $14.2 million in 2015, then dropped by 24.33% to $10.7 million in 2016, then increased by 20.20% to $12.9 million in 2017, then climbed by 7.93% to $13.9 million in 2018.
  • Its last three reported values are $13.9 million in Q4 2018, $12.9 million for Q3 2018, and $12.9 million during Q2 2018.